IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+1.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.9M | 14.2M | 11.0M | 19.0M | 39.9M |
| Cost of Revenue | 13.0K | — | — | — | — |
| Gross Profit | 9.8M | 14.2M | 11.0M | 19.0M | 39.9M |
| Operating Expenses | |||||
| R&D Expense | 38.6M | 30.8M | 26.9M | 17.7M | 14.4M |
| SG&A Expense | 21.8M | 22.0M | 18.2M | 12.0M | 7.3M |
| General & Admin Expense | 21.8M | 22.0M | 18.2M | 12.0M | 7.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 28.0M | — | — |
| Total Operating Expenses | 60.5M | 52.8M | 73.1M | 29.6M | 21.6M |
| Cost and Expenses | 60.5M | 52.8M | 73.1M | 29.6M | 21.6M |
| Operating Income (EBIT) | (50.6M) | (38.6M) | (62.1M) | (10.6M) | 18.2M |
| Non-Operating | |||||
| Interest Income | 800.0K | — | — | — | — |
| Interest Expense | 2.6M | 1.5M | — | 1.3M | 9.0K |
| Net Interest Income | (1.8M) | (1.5M) | — | (1.3M) | (9.0K) |
| Other Non-Op Income/Expense | (57.0M) | (11.0M) | 4.5M | 589.0K | (23.0K) |
| Non-Operating Income (excl Interest) | 54.4M | 9.5M | (4.5M) | (589.0K) | 14.0K |
| EBT (Pre-Tax Income) | (107.6M) | (49.6M) | (57.5M) | (10.0M) | 18.2M |
| Income Tax Expense | — | — | — | 12.0K | 315.0K |
| Bottom Line | |||||
| Net Income | (107.6M) | (49.6M) | (57.5M) | (10.0M) | 17.9M |
| Earnings from Cont. Ops | (107.6M) | (49.6M) | (57.5M) | (10.0M) | 17.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (107.6M) | (49.6M) | (57.5M) | (10.0M) | 17.9M |
| Per Share | |||||
| Basic EPS | ($1.27) | ($0.80) | ($2.15) | ($0.46) | $0.90 |
| Diluted EPS | ($1.27) | ($0.80) | ($2.15) | ($0.46) | $0.87 |
| Revenue Per Share | $0.10 | $0.02 | $0.41 | $0.88 | $2.00 |
| Shares | |||||
| Basic Shares Outstanding | 95.5M | 622.2M | 26.7M | 21.6M | 19.9M |
| Diluted Shares Outstanding | 111.4M | 622.2M | 26.7M | 21.6M | 20.6M |
| Profitability Metrics | |||||
| EBITDA | (104.9M) | (48.1M) | (57.5M) | (10.0M) | 18.2M |
| D&A | 39.0K | 53.0K | 10.0K | 6.0K | 4.0K |
| EBIT | (105.0M) | (48.1M) | (57.5M) | (10.0M) | 18.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026